TrialOrphanet journal of rare diseases2022

Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia.

K P Thompson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.